<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01253226</url>
  </required_header>
  <id_info>
    <org_study_id>13060</org_study_id>
    <secondary_id>H9B-JE-BCDK</secondary_id>
    <nct_id>NCT01253226</nct_id>
  </id_info>
  <brief_title>A Study for Japanese Participants With Rheumatoid Arthritis (RA)</brief_title>
  <official_title>Multiple-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2127399 in Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of multiple doses of LY2127399
      (tabalumab) in Japanese participants with RA. The study consists of a 20-week treatment
      period. All participants will be followed for up to 12 weeks after the last study drug
      administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) [Clinically Significant Effects]</measure>
    <time_frame>Baseline through study completion (up to Week 32 plus up to 12 weeks for B cell monitoring)</time_frame>
    <description>Clinically significant effects are defined as serious AEs (SAEs) and other non-serious AEs regardless of causality. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of Tabalumab: Area Under the Concentration Time Curve (AUC)</measure>
    <time_frame>Week 0: Day 1 [predose and 1 hour (h), 3 h, and 6 h postdose], Days 2, 3, and 5, and Weeks 1, 2, 3, and 4 postdose</time_frame>
    <description>The following parameters are reported for the first SC injection of tabalumab: AUC(0-tlast) defined as AUC from time 0 to time t, where t is the time at the end of the dosing interval; AUC(0-2W) defined as AUC from time 0 to Week 2; and AUC(0-tau) defined as AUC during 1 dosing interval at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of Tabalumab: Maximum Observed Drug Concentration (Cmax)</measure>
    <time_frame>Week 0: Day 1 Predose, 1 h, 3 h, and 6 h postdose</time_frame>
    <description>Cmax for the first SC injection of tabalumab is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in B Cell [Cluster Designation 20+ (CD20+)] Counts</measure>
    <time_frame>Baseline, Week 0 (Day 2), Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, and 32</time_frame>
    <description>B-lymphocyte antigen, CD20+, is an activated-glycosylated phosphoprotein expressed on the surface of all mature B cells. Percent change from baseline in B cell counts=[(post-baseline CD20+ B cell count-baseline CD20+ B cell count)/(baseline CD20+ B cell count)]*100. A negative change indicates a decrease in cell count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibody [Inova Enzyme-Linked Immunosorbent Assay (ELISA) Method]</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>During the analysis of anti-CCP, the analytical method was changed from the Inova ELISA method to the Roche Cobas 6000 method due to the discontinuation of a reagent used in the Inova ELISA method. The anti-CCP data are summarized separately for samples collected before and after the method change. No post-baseline samples from the 120 mg tabalumab Q4W and Q2W cohorts were analyzed using the Inova ELISA method. For both methods, a decrease in anti-CCP antibodies indicated an improvement in the participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Anti-CCP Antibody (Roche Cobas 6000 Method)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>During the analysis of anti-CCP, the analytical method was changed from the Inova ELISA method to the Roche Cobas 6000 method due to the discontinuation of a reagent used in the Inova ELISA method. The anti-CCP data are summarized separately for samples collected before and after the method change. No baseline samples from the 30 mg, 60 mg, and 120 mg tabalumab Q4W cohorts were analyzed using the Roche Cobas 6000 method. For both methods, a decrease in anti-CCP antibodies indicated an improvement in the participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rheumatoid Factor (RF)</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>RF is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis (RA). Higher RF levels indicate an aggressive RA and a higher risk of joint damage. A decrease in RF levels indicate an improvement in the participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Serum Immunoglobulins (IgG, IgM, IgA)</measure>
    <time_frame>Baseline, Weeks 4, 16, 24, and 32</time_frame>
    <description>Immunoglobulins, or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Change from baseline serum immunoglobulin G (IgG), immunoglobulin M (IgM), and immunoglobulin A (IgA) levels are reported. A negative change indicates a decrease in immunoglobulin levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in CRP</measure>
    <time_frame>Baseline, Weeks 4, 8, 16, and 24</time_frame>
    <description>CRP is an indicator of inflammation. The percent change from baseline in CRP=[(post-baseline CRP- baseline CRP)/(baseline CRP)]*100. A negative change indicates an improvement in the participant's condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>Baseline, Weeks 4, 8, 16, and 24</time_frame>
    <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Reference ranges are gender-specific and can vary slightly among laboratories. The normal range is approximately ≤10 millimeters per hour (mm/h) for males and ≤20 mm/h for females. Higher scores indicate greater inflammation. The percent change from baseline in ESR=[(post-baseline ESR- baseline ESR)/(baseline ESR)]*100. A decrease in ESR indicates an improvement in the participant's condition.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>30 milligrams (mg) Tabalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 mg tabalumab every 4 weeks (Q4W) for 20 weeks (6 doses of study drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 mg Tabalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg tabalumab Q4W for 20 weeks (6 doses of study drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg Tabalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 mg tabalumab Q4W for 20 weeks (6 doses of study drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q4W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Q4W for 20 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg once every 2 weeks (Q2W) Tabalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial loading dose of 240 mg tabalumab followed by 120 mg Q2W for 20 weeks (10 doses of study drug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Q2W for 20 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2127399 (Tabalumab)</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>120 mg Tabalumab</arm_group_label>
    <arm_group_label>120 mg once every 2 weeks (Q2W) Tabalumab</arm_group_label>
    <arm_group_label>30 milligrams (mg) Tabalumab</arm_group_label>
    <arm_group_label>60 mg Tabalumab</arm_group_label>
    <other_name>LY2127399</other_name>
    <other_name>Tabalumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>Placebo Q2W</arm_group_label>
    <arm_group_label>Placebo Q4W</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have given written informed consent

          -  Women must not be pregnant, breastfeeding or be at risk to become pregnant during
             study participation

          -  Diagnosis of RA

          -  Active RA

          -  Current, regular use of Methotrexate, at a stable dose

          -  Body weight between 40 and 105 kilograms (kg), inclusive

        Exclusion Criteria:

          -  Use of excluded medications (reviewed by study doctor)

          -  Have medical findings which, in the opinion of the study doctor, put participant at an
             unacceptable risk for participation in the study

          -  Have had recent or ongoing infection which, in the opinion of the study doctor put
             participant at an unacceptable risk for participation

          -  Evidence of tuberculosis

          -  Have systemic inflammatory condition other than RA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM-5 PM Eastern time (UTC/GMT - 5 hours, EST )</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukui</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ibaragi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <results_first_submitted>March 24, 2018</results_first_submitted>
  <results_first_submitted_qc>October 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2018</results_first_posted>
  <last_update_submitted>October 19, 2018</last_update_submitted>
  <last_update_submitted_qc>October 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This dose-escalation study had 4 cohorts. Each cohort included 6 LY2127399 (tabalumab) participants and 2 placebo participants. Participants treated once every 2 weeks (Q2W) or once every 4 weeks (Q4W) and had a follow-up visit at Week 32. Additional visits beyond Week 32 were scheduled, as needed, for B cell count monitoring (up to 12 weeks).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>30 mg Tabalumab Q4W</title>
          <description>Tabalumab: 30 milligrams (mg) subcutaneous (SC) injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
        </group>
        <group group_id="P2">
          <title>60 mg Tabalumab Q4W</title>
          <description>Tabalumab: 60 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
        </group>
        <group group_id="P3">
          <title>120 mg Tabalumab Q4W</title>
          <description>Tabalumab: 120 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
        </group>
        <group group_id="P4">
          <title>120 mg Tabalumab Q2W</title>
          <description>Tabalumab: 240 mg SC injection given as a loading dose at Week 0 followed by 120 mg SC injection Q2W for 20 weeks (Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Q4W cohorts: Placebo SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).
Q2W cohort: Placebo SC injection Q2W for 20 weeks (Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo).</population>
      <group_list>
        <group group_id="B1">
          <title>30 mg Tabalumab Q4W</title>
          <description>Tabalumab: 30 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
        </group>
        <group group_id="B2">
          <title>60 mg Tabalumab Q4W</title>
          <description>Tabalumab: 60 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
        </group>
        <group group_id="B3">
          <title>120 mg Tabalumab Q4W</title>
          <description>Tabalumab: 120 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
        </group>
        <group group_id="B4">
          <title>120 mg Tabalumab Q2W</title>
          <description>Tabalumab: 240 mg SC injection given as a loading dose at Week 0 followed by 120 mg SC injection Q2W for 20 weeks (Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Q4W cohorts: Placebo SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).
Q2W cohort: Placebo SC injection Q2W for 20 weeks (Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.0" spread="5.9"/>
                    <measurement group_id="B2" value="50.0" spread="15.0"/>
                    <measurement group_id="B3" value="55.5" spread="14.2"/>
                    <measurement group_id="B4" value="56.7" spread="8.0"/>
                    <measurement group_id="B5" value="58.4" spread="17.1"/>
                    <measurement group_id="B6" value="57.4" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Use of Corticosteroids</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Weight</title>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="5.5"/>
                    <measurement group_id="B2" value="55.9" spread="13.8"/>
                    <measurement group_id="B3" value="55.9" spread="10.5"/>
                    <measurement group_id="B4" value="58.3" spread="8.3"/>
                    <measurement group_id="B5" value="54.6" spread="7.5"/>
                    <measurement group_id="B6" value="55.8" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-Reactive Protein (CRP)</title>
          <description>CRP is an indicator of inflammation. Higher values indicate a greater amount of inflammation</description>
          <units>milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.46" spread="13.90"/>
                    <measurement group_id="B2" value="18.69" spread="35.23"/>
                    <measurement group_id="B3" value="14.91" spread="9.17"/>
                    <measurement group_id="B4" value="8.73" spread="8.26"/>
                    <measurement group_id="B5" value="11.07" spread="5.30"/>
                    <measurement group_id="B6" value="12.85" spread="16.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs) [Clinically Significant Effects]</title>
        <description>Clinically significant effects are defined as serious AEs (SAEs) and other non-serious AEs regardless of causality. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.</description>
        <time_frame>Baseline through study completion (up to Week 32 plus up to 12 weeks for B cell monitoring)</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg Tabalumab Q4W</title>
            <description>Tabalumab: 30 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O2">
            <title>60 mg Tabalumab Q4W</title>
            <description>Tabalumab: 60 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O3">
            <title>120 mg Tabalumab Q4W</title>
            <description>Tabalumab: 120 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O4">
            <title>120 mg Tabalumab Q2W</title>
            <description>Tabalumab: 240 mg SC injection given as a loading dose at Week 0 followed by 120 mg SC injection Q2W for 20 weeks (Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Q4W cohorts: Placebo SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).
Q2W cohort: Placebo SC injection Q2W for 20 weeks (Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) [Clinically Significant Effects]</title>
          <description>Clinically significant effects are defined as serious AEs (SAEs) and other non-serious AEs regardless of causality. A summary of SAEs and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.</description>
          <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs, all causes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious AEs, all causes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK) of Tabalumab: Area Under the Concentration Time Curve (AUC)</title>
        <description>The following parameters are reported for the first SC injection of tabalumab: AUC(0-tlast) defined as AUC from time 0 to time t, where t is the time at the end of the dosing interval; AUC(0-2W) defined as AUC from time 0 to Week 2; and AUC(0-tau) defined as AUC during 1 dosing interval at steady state.</description>
        <time_frame>Week 0: Day 1 [predose and 1 hour (h), 3 h, and 6 h postdose], Days 2, 3, and 5, and Weeks 1, 2, 3, and 4 postdose</time_frame>
        <population>Randomized participants who received at least 1 dose of tabalumab and had evaluable AUC data.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg Tabalumab Q4W</title>
            <description>Tabalumab: 30 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O2">
            <title>60 mg Tabalumab Q4W</title>
            <description>Tabalumab: 60 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O3">
            <title>120 mg Tabalumab Q4W</title>
            <description>Tabalumab: 120 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O4">
            <title>120 mg Tabalumab Q2W</title>
            <description>Tabalumab: 240 mg SC injection given as a loading dose at Week 0 followed by 120 mg SC injection Q2W for 20 weeks (Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK) of Tabalumab: Area Under the Concentration Time Curve (AUC)</title>
          <description>The following parameters are reported for the first SC injection of tabalumab: AUC(0-tlast) defined as AUC from time 0 to time t, where t is the time at the end of the dosing interval; AUC(0-2W) defined as AUC from time 0 to Week 2; and AUC(0-tau) defined as AUC during 1 dosing interval at steady state.</description>
          <population>Randomized participants who received at least 1 dose of tabalumab and had evaluable AUC data.</population>
          <units>micrograms*day/milliliter (mcg*day/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-tlast)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0" spread="24"/>
                    <measurement group_id="O2" value="148" spread="38"/>
                    <measurement group_id="O3" value="303" spread="49"/>
                    <measurement group_id="O4" value="303" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-2W)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="26"/>
                    <measurement group_id="O2" value="86.5" spread="34"/>
                    <measurement group_id="O3" value="170" spread="46"/>
                    <measurement group_id="O4" value="280" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-tau)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.5" spread="27"/>
                    <measurement group_id="O2" value="173" spread="NA">Only 1 participant included in the analysis, therefore the geometric coefficient of variation is not calculable.</measurement>
                    <measurement group_id="O3" value="260" spread="58"/>
                    <measurement group_id="O4" value="280" spread="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK of Tabalumab: Maximum Observed Drug Concentration (Cmax)</title>
        <description>Cmax for the first SC injection of tabalumab is reported.</description>
        <time_frame>Week 0: Day 1 Predose, 1 h, 3 h, and 6 h postdose</time_frame>
        <population>Randomized participants who received at least 1 dose of tabalumab and had evaluable Cmax data.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg Tabalumab Q4W</title>
            <description>Tabalumab: 30 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O2">
            <title>60 mg Tabalumab Q4W</title>
            <description>Tabalumab: 60 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O3">
            <title>120 mg Tabalumab Q4W</title>
            <description>Tabalumab: 120 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O4">
            <title>120 mg Tabalumab Q2W</title>
            <description>Tabalumab: 240 mg SC injection given as a loading dose at Week 0 followed by 120 mg SC injection Q2W for 20 weeks (Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
        </group_list>
        <measure>
          <title>PK of Tabalumab: Maximum Observed Drug Concentration (Cmax)</title>
          <description>Cmax for the first SC injection of tabalumab is reported.</description>
          <population>Randomized participants who received at least 1 dose of tabalumab and had evaluable Cmax data.</population>
          <units>micrograms per milliliter (mcg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="26"/>
                    <measurement group_id="O2" value="7.61" spread="35"/>
                    <measurement group_id="O3" value="16.6" spread="61"/>
                    <measurement group_id="O4" value="25.0" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in B Cell [Cluster Designation 20+ (CD20+)] Counts</title>
        <description>B-lymphocyte antigen, CD20+, is an activated-glycosylated phosphoprotein expressed on the surface of all mature B cells. Percent change from baseline in B cell counts=[(post-baseline CD20+ B cell count-baseline CD20+ B cell count)/(baseline CD20+ B cell count)]*100. A negative change indicates a decrease in cell count.</description>
        <time_frame>Baseline, Week 0 (Day 2), Weeks 1, 2, 3, 4, 6, 8, 12, 16, 20, 24, and 32</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline B cell assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg Tabalumab Q4W</title>
            <description>Tabalumab: 30 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O2">
            <title>60 mg Tabalumab Q4W</title>
            <description>Tabalumab: 60 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O3">
            <title>120 mg Tabalumab Q4W</title>
            <description>Tabalumab: 120 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O4">
            <title>120 mg Tabalumab Q2W</title>
            <description>Tabalumab: 240 mg SC injection given as a loading dose at Week 0 followed by 120 mg SC injection Q2W for 20 weeks (Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Q4W cohorts: Placebo SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).
Q2W cohort: Placebo SC injection Q2W for 20 weeks (Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in B Cell [Cluster Designation 20+ (CD20+)] Counts</title>
          <description>B-lymphocyte antigen, CD20+, is an activated-glycosylated phosphoprotein expressed on the surface of all mature B cells. Percent change from baseline in B cell counts=[(post-baseline CD20+ B cell count-baseline CD20+ B cell count)/(baseline CD20+ B cell count)]*100. A negative change indicates a decrease in cell count.</description>
          <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline B cell assessment.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0 (Day 2)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="20.7"/>
                    <measurement group_id="O2" value="15.6" spread="60.0"/>
                    <measurement group_id="O3" value="16.1" spread="22.5"/>
                    <measurement group_id="O4" value="13.7" spread="34.4"/>
                    <measurement group_id="O5" value="34.9" spread="49.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" spread="25.8"/>
                    <measurement group_id="O2" value="82.1" spread="107.8"/>
                    <measurement group_id="O3" value="100.7" spread="91.2"/>
                    <measurement group_id="O4" value="55.3" spread="53.9"/>
                    <measurement group_id="O5" value="-7.2" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="34.5"/>
                    <measurement group_id="O2" value="48.2" spread="80.2"/>
                    <measurement group_id="O3" value="73.0" spread="58.8"/>
                    <measurement group_id="O4" value="53.7" spread="12.9"/>
                    <measurement group_id="O5" value="-12.0" spread="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="33.7"/>
                    <measurement group_id="O2" value="45.4" spread="63.3"/>
                    <measurement group_id="O3" value="65.7" spread="63.5"/>
                    <measurement group_id="O4" value="43.1" spread="23.3"/>
                    <measurement group_id="O5" value="0.3" spread="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" spread="36.7"/>
                    <measurement group_id="O2" value="31.0" spread="81.6"/>
                    <measurement group_id="O3" value="46.1" spread="58.4"/>
                    <measurement group_id="O4" value="13.1" spread="32.1"/>
                    <measurement group_id="O5" value="5.5" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="42.8"/>
                    <measurement group_id="O2" value="10.9" spread="65.9"/>
                    <measurement group_id="O3" value="67.7" spread="69.4"/>
                    <measurement group_id="O4" value="48.9" spread="43.2"/>
                    <measurement group_id="O5" value="2.1" spread="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="37.3"/>
                    <measurement group_id="O2" value="2.2" spread="57.0"/>
                    <measurement group_id="O3" value="36.7" spread="58.6"/>
                    <measurement group_id="O4" value="5.9" spread="46.0"/>
                    <measurement group_id="O5" value="2.9" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.6" spread="31.7"/>
                    <measurement group_id="O2" value="-0.4" spread="76.3"/>
                    <measurement group_id="O3" value="22.8" spread="60.7"/>
                    <measurement group_id="O4" value="10.0" spread="38.6"/>
                    <measurement group_id="O5" value="-7.0" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="32.4"/>
                    <measurement group_id="O2" value="-37.9" spread="27.1"/>
                    <measurement group_id="O3" value="27.0" spread="74.1"/>
                    <measurement group_id="O4" value="-8.3" spread="29.2"/>
                    <measurement group_id="O5" value="0.6" spread="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.4" spread="32.8"/>
                    <measurement group_id="O2" value="-17.1" spread="59.1"/>
                    <measurement group_id="O3" value="54.1" spread="72.6"/>
                    <measurement group_id="O4" value="-13.4" spread="30.7"/>
                    <measurement group_id="O5" value="2.5" spread="65.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.4" spread="32.3"/>
                    <measurement group_id="O2" value="-51.7" spread="25.9"/>
                    <measurement group_id="O3" value="26.4" spread="76.3"/>
                    <measurement group_id="O4" value="-30.4" spread="26.3"/>
                    <measurement group_id="O5" value="-2.9" spread="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.0" spread="17.9"/>
                    <measurement group_id="O2" value="-50.7" spread="36.1"/>
                    <measurement group_id="O3" value="-17.9" spread="31.1"/>
                    <measurement group_id="O4" value="-38.7" spread="17.8"/>
                    <measurement group_id="O5" value="-4.0" spread="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibody [Inova Enzyme-Linked Immunosorbent Assay (ELISA) Method]</title>
        <description>During the analysis of anti-CCP, the analytical method was changed from the Inova ELISA method to the Roche Cobas 6000 method due to the discontinuation of a reagent used in the Inova ELISA method. The anti-CCP data are summarized separately for samples collected before and after the method change. No post-baseline samples from the 120 mg tabalumab Q4W and Q2W cohorts were analyzed using the Inova ELISA method. For both methods, a decrease in anti-CCP antibodies indicated an improvement in the participant's condition.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline anti-CCP assessment using the Inova ELISA method. No participants were analyzed in the 120 mg tabalumab Q4W and Q2W cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg Tabalumab Q4W</title>
            <description>Tabalumab: 30 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O2">
            <title>60 mg Tabalumab Q4W</title>
            <description>Tabalumab: 60 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O3">
            <title>120 mg Tabalumab Q4W</title>
            <description>Tabalumab: 120 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O4">
            <title>120 mg Tabalumab Q2W</title>
            <description>Tabalumab: 240 mg SC injection given as a loading dose at Week 0 followed by 120 mg SC injection Q2W for 20 weeks (Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Q4W cohorts: Placebo SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).
Q2W cohort: Placebo SC injection Q2W for 20 weeks (Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Anti-Cyclic Citrullinated Peptide (Anti-CCP) Antibody [Inova Enzyme-Linked Immunosorbent Assay (ELISA) Method]</title>
          <description>During the analysis of anti-CCP, the analytical method was changed from the Inova ELISA method to the Roche Cobas 6000 method due to the discontinuation of a reagent used in the Inova ELISA method. The anti-CCP data are summarized separately for samples collected before and after the method change. No post-baseline samples from the 120 mg tabalumab Q4W and Q2W cohorts were analyzed using the Inova ELISA method. For both methods, a decrease in anti-CCP antibodies indicated an improvement in the participant's condition.</description>
          <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline anti-CCP assessment using the Inova ELISA method. No participants were analyzed in the 120 mg tabalumab Q4W and Q2W cohorts.</population>
          <units>units (U)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.3" spread="138.8"/>
                    <measurement group_id="O2" value="63.3" spread="337.0"/>
                    <measurement group_id="O5" value="9.3" spread="58.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Anti-CCP Antibody (Roche Cobas 6000 Method)</title>
        <description>During the analysis of anti-CCP, the analytical method was changed from the Inova ELISA method to the Roche Cobas 6000 method due to the discontinuation of a reagent used in the Inova ELISA method. The anti-CCP data are summarized separately for samples collected before and after the method change. No baseline samples from the 30 mg, 60 mg, and 120 mg tabalumab Q4W cohorts were analyzed using the Roche Cobas 6000 method. For both methods, a decrease in anti-CCP antibodies indicated an improvement in the participant's condition.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline anti-CCP assessment using the Roche Cobas 6000 method. No participants were analyzed in the 30 mg, 60 mg, and 120 mg tabalumab Q4W cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg Tabalumab Q4W</title>
            <description>Tabalumab: 30 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O2">
            <title>60 mg Tabalumab Q4W</title>
            <description>Tabalumab: 60 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O3">
            <title>120 mg Tabalumab Q4W</title>
            <description>Tabalumab: 120 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O4">
            <title>120 mg Tabalumab Q2W</title>
            <description>Tabalumab: 240 mg SC injection given as a loading dose at Week 0 followed by 120 mg SC injection Q2W for 20 weeks (Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Q4W cohorts: Placebo SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).
Q2W cohort: Placebo SC injection Q2W for 20 weeks (Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Anti-CCP Antibody (Roche Cobas 6000 Method)</title>
          <description>During the analysis of anti-CCP, the analytical method was changed from the Inova ELISA method to the Roche Cobas 6000 method due to the discontinuation of a reagent used in the Inova ELISA method. The anti-CCP data are summarized separately for samples collected before and after the method change. No baseline samples from the 30 mg, 60 mg, and 120 mg tabalumab Q4W cohorts were analyzed using the Roche Cobas 6000 method. For both methods, a decrease in anti-CCP antibodies indicated an improvement in the participant's condition.</description>
          <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline anti-CCP assessment using the Roche Cobas 6000 method. No participants were analyzed in the 30 mg, 60 mg, and 120 mg tabalumab Q4W cohorts.</population>
          <units>units per milliliter (U/mL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="NA" lower_limit="0.0" upper_limit="35.5">Only 2 participants included in the analysis, therefore median is not calculable.</measurement>
                    <measurement group_id="O5" value="NA" lower_limit="0.0" upper_limit="0.00">Only 1 participant included in the analysis, therefore median is not calculable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rheumatoid Factor (RF)</title>
        <description>RF is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis (RA). Higher RF levels indicate an aggressive RA and a higher risk of joint damage. A decrease in RF levels indicate an improvement in the participant's condition.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline RF level assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg Tabalumab Q4W</title>
            <description>Tabalumab: 30 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O2">
            <title>60 mg Tabalumab Q4W</title>
            <description>Tabalumab: 60 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O3">
            <title>120 mg Tabalumab Q4W</title>
            <description>Tabalumab: 120 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O4">
            <title>120 mg Tabalumab Q2W</title>
            <description>Tabalumab: 240 mg SC injection given as a loading dose at Week 0 followed by 120 mg SC injection Q2W for 20 weeks (Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Q4W cohorts: Placebo SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).
Q2W cohort: Placebo SC injection Q2W for 20 weeks (Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rheumatoid Factor (RF)</title>
          <description>RF is an autoantibody (antibody directed against an organism's own tissues) most relevant in rheumatoid arthritis (RA). Higher RF levels indicate an aggressive RA and a higher risk of joint damage. A decrease in RF levels indicate an improvement in the participant's condition.</description>
          <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline RF level assessment.</population>
          <units>kilo units per liter (kU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.6" spread="23.2"/>
                    <measurement group_id="O2" value="29.6" spread="143.9"/>
                    <measurement group_id="O3" value="-108.0" spread="97.0"/>
                    <measurement group_id="O4" value="-41.5" spread="45.0"/>
                    <measurement group_id="O5" value="-12.9" spread="76.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Serum Immunoglobulins (IgG, IgM, IgA)</title>
        <description>Immunoglobulins, or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Change from baseline serum immunoglobulin G (IgG), immunoglobulin M (IgM), and immunoglobulin A (IgA) levels are reported. A negative change indicates a decrease in immunoglobulin levels.</description>
        <time_frame>Baseline, Weeks 4, 16, 24, and 32</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline serum immunoglobulin assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg Tabalumab Q4W</title>
            <description>Tabalumab: 30 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O2">
            <title>60 mg Tabalumab Q4W</title>
            <description>Tabalumab: 60 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O3">
            <title>120 mg Tabalumab Q4W</title>
            <description>Tabalumab: 120 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O4">
            <title>120 mg Tabalumab Q2W</title>
            <description>Tabalumab: 240 mg SC injection given as a loading dose at Week 0 followed by 120 mg SC injection Q2W for 20 weeks (Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Q4W cohorts: Placebo SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).
Q2W cohort: Placebo SC injection Q2W for 20 weeks (Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Serum Immunoglobulins (IgG, IgM, IgA)</title>
          <description>Immunoglobulins, or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses. Their normal blood levels indicate proper immune status. Change from baseline serum immunoglobulin G (IgG), immunoglobulin M (IgM), and immunoglobulin A (IgA) levels are reported. A negative change indicates a decrease in immunoglobulin levels.</description>
          <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline serum immunoglobulin assessment.</population>
          <units>grams per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgG, Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.6"/>
                    <measurement group_id="O2" value="0.0" spread="0.7"/>
                    <measurement group_id="O3" value="0.5" spread="2.5"/>
                    <measurement group_id="O4" value="-0.6" spread="1.0"/>
                    <measurement group_id="O5" value="-0.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG, Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="1.0"/>
                    <measurement group_id="O2" value="-0.2" spread="2.6"/>
                    <measurement group_id="O3" value="-1.4" spread="1.0"/>
                    <measurement group_id="O4" value="-1.8" spread="1.4"/>
                    <measurement group_id="O5" value="-0.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG, Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="1.1"/>
                    <measurement group_id="O2" value="-0.7" spread="2.8"/>
                    <measurement group_id="O3" value="-2.1" spread="2.5"/>
                    <measurement group_id="O4" value="-0.8" spread="0.8"/>
                    <measurement group_id="O5" value="-0.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG, Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="1.3"/>
                    <measurement group_id="O2" value="-0.9" spread="2.4"/>
                    <measurement group_id="O3" value="-2.7" spread="2.1"/>
                    <measurement group_id="O4" value="-0.9" spread="1.2"/>
                    <measurement group_id="O5" value="0.4" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM, Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.5"/>
                    <measurement group_id="O2" value="-0.1" spread="0.1"/>
                    <measurement group_id="O3" value="-0.2" spread="0.1"/>
                    <measurement group_id="O4" value="-0.1" spread="0.0"/>
                    <measurement group_id="O5" value="-0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM, Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.6"/>
                    <measurement group_id="O2" value="-0.3" spread="0.3"/>
                    <measurement group_id="O3" value="-0.2" spread="0.2"/>
                    <measurement group_id="O4" value="-0.2" spread="0.1"/>
                    <measurement group_id="O5" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM, Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.7"/>
                    <measurement group_id="O2" value="-0.3" spread="0.2"/>
                    <measurement group_id="O3" value="-0.3" spread="0.3"/>
                    <measurement group_id="O4" value="-0.2" spread="0.1"/>
                    <measurement group_id="O5" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgM, Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.8"/>
                    <measurement group_id="O2" value="-0.3" spread="0.3"/>
                    <measurement group_id="O3" value="-0.4" spread="0.1"/>
                    <measurement group_id="O4" value="-0.2" spread="0.1"/>
                    <measurement group_id="O5" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA, Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.2"/>
                    <measurement group_id="O2" value="-0.2" spread="0.2"/>
                    <measurement group_id="O3" value="-0.4" spread="0.3"/>
                    <measurement group_id="O4" value="-0.1" spread="0.4"/>
                    <measurement group_id="O5" value="-0.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA, Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.3"/>
                    <measurement group_id="O2" value="-0.4" spread="0.2"/>
                    <measurement group_id="O3" value="-0.5" spread="0.2"/>
                    <measurement group_id="O4" value="-0.3" spread="0.4"/>
                    <measurement group_id="O5" value="-0.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA, Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.2"/>
                    <measurement group_id="O2" value="-0.5" spread="0.3"/>
                    <measurement group_id="O3" value="-0.6" spread="0.4"/>
                    <measurement group_id="O4" value="-0.4" spread="0.3"/>
                    <measurement group_id="O5" value="-0.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgA, Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.4"/>
                    <measurement group_id="O2" value="-0.5" spread="0.4"/>
                    <measurement group_id="O3" value="-0.7" spread="0.4"/>
                    <measurement group_id="O4" value="-0.3" spread="0.2"/>
                    <measurement group_id="O5" value="-0.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in CRP</title>
        <description>CRP is an indicator of inflammation. The percent change from baseline in CRP=[(post-baseline CRP- baseline CRP)/(baseline CRP)]*100. A negative change indicates an improvement in the participant's condition.</description>
        <time_frame>Baseline, Weeks 4, 8, 16, and 24</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline CRP assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg Tabalumab Q4W</title>
            <description>Tabalumab: 30 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O2">
            <title>60 mg Tabalumab Q4W</title>
            <description>Tabalumab: 60 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O3">
            <title>120 mg Tabalumab Q4W</title>
            <description>Tabalumab: 120 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O4">
            <title>120 mg Tabalumab Q2W</title>
            <description>Tabalumab: 240 mg SC injection given as a loading dose at Week 0 followed by 120 mg SC injection Q2W for 20 weeks (Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Q4W cohorts: Placebo SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).
Q2W cohort: Placebo SC injection Q2W for 20 weeks (Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in CRP</title>
          <description>CRP is an indicator of inflammation. The percent change from baseline in CRP=[(post-baseline CRP- baseline CRP)/(baseline CRP)]*100. A negative change indicates an improvement in the participant's condition.</description>
          <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline CRP assessment.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210.8" spread="624.0"/>
                    <measurement group_id="O2" value="-16.0" spread="53.1"/>
                    <measurement group_id="O3" value="-8.5" spread="56.7"/>
                    <measurement group_id="O4" value="16.8" spread="111.9"/>
                    <measurement group_id="O5" value="42.9" spread="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.0" spread="16.6"/>
                    <measurement group_id="O2" value="18.1" spread="126.4"/>
                    <measurement group_id="O3" value="167.0" spread="537.9"/>
                    <measurement group_id="O4" value="31.6" spread="85.9"/>
                    <measurement group_id="O5" value="-13.8" spread="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.1" spread="76.3"/>
                    <measurement group_id="O2" value="840.8" spread="2138.7"/>
                    <measurement group_id="O3" value="-83.1" spread="15.0"/>
                    <measurement group_id="O4" value="-41.3" spread="15.4"/>
                    <measurement group_id="O5" value="19.8" spread="120.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.9" spread="43.9"/>
                    <measurement group_id="O2" value="-33.5" spread="40.8"/>
                    <measurement group_id="O3" value="-75.5" spread="36.4"/>
                    <measurement group_id="O4" value="119.9" spread="147.7"/>
                    <measurement group_id="O5" value="39.6" spread="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Erythrocyte Sedimentation Rate (ESR)</title>
        <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Reference ranges are gender-specific and can vary slightly among laboratories. The normal range is approximately ≤10 millimeters per hour (mm/h) for males and ≤20 mm/h for females. Higher scores indicate greater inflammation. The percent change from baseline in ESR=[(post-baseline ESR- baseline ESR)/(baseline ESR)]*100. A decrease in ESR indicates an improvement in the participant's condition.</description>
        <time_frame>Baseline, Weeks 4, 8, 16, and 24</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline ESR assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>30 mg Tabalumab Q4W</title>
            <description>Tabalumab: 30 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O2">
            <title>60 mg Tabalumab Q4W</title>
            <description>Tabalumab: 60 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O3">
            <title>120 mg Tabalumab Q4W</title>
            <description>Tabalumab: 120 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
          </group>
          <group group_id="O4">
            <title>120 mg Tabalumab Q2W</title>
            <description>Tabalumab: 240 mg SC injection given as a loading dose at Week 0 followed by 120 mg SC injection Q2W for 20 weeks (Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Q4W cohorts: Placebo SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).
Q2W cohort: Placebo SC injection Q2W for 20 weeks (Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Erythrocyte Sedimentation Rate (ESR)</title>
          <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Reference ranges are gender-specific and can vary slightly among laboratories. The normal range is approximately ≤10 millimeters per hour (mm/h) for males and ≤20 mm/h for females. Higher scores indicate greater inflammation. The percent change from baseline in ESR=[(post-baseline ESR- baseline ESR)/(baseline ESR)]*100. A decrease in ESR indicates an improvement in the participant's condition.</description>
          <population>Randomized participants who received at least 1 dose of study drug (tabalumab or placebo) and had a baseline and at least 1 post-baseline ESR assessment.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="31.8"/>
                    <measurement group_id="O2" value="-22.0" spread="22.4"/>
                    <measurement group_id="O3" value="-7.5" spread="32.4"/>
                    <measurement group_id="O4" value="11.7" spread="28.4"/>
                    <measurement group_id="O5" value="6.1" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.5" spread="22.1"/>
                    <measurement group_id="O2" value="-23.3" spread="24.7"/>
                    <measurement group_id="O3" value="-3.1" spread="55.9"/>
                    <measurement group_id="O4" value="8.9" spread="33.3"/>
                    <measurement group_id="O5" value="13.3" spread="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.1" spread="38.2"/>
                    <measurement group_id="O2" value="-28.7" spread="25.0"/>
                    <measurement group_id="O3" value="-47.4" spread="27.4"/>
                    <measurement group_id="O4" value="-18.4" spread="16.4"/>
                    <measurement group_id="O5" value="-3.0" spread="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.7" spread="20.4"/>
                    <measurement group_id="O2" value="-42.4" spread="26.4"/>
                    <measurement group_id="O3" value="-56.4" spread="28.1"/>
                    <measurement group_id="O4" value="22.3" spread="64.2"/>
                    <measurement group_id="O5" value="26.3" spread="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through study completion (up to Week 32 plus up to 12 weeks for B cell monitoring)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>30 mg Tabalumab Q4W</title>
          <description>Tabalumab: 30 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
        </group>
        <group group_id="E2">
          <title>60 mg Tabalumab Q4W</title>
          <description>Tabalumab: 60 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
        </group>
        <group group_id="E3">
          <title>120 mg Tabalumab Q4W</title>
          <description>Tabalumab: 120 mg SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).</description>
        </group>
        <group group_id="E4">
          <title>120 mg Tabalumab Q2W</title>
          <description>Tabalumab: 240 mg SC injection given as a loading dose at Week 0 followed by 120 mg SC injection Q2W for 20 weeks (Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Q4W cohorts: Placebo SC injection Q4W for 20 weeks (Weeks 0, 4, 8, 12, 16, and 20).
Q2W cohort: Placebo SC injection Q2W for 20 weeks (Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYE MOVEMENT DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>OCULAR HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>STRABISMUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA LEGIONELLA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVAL ABRASION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CHALAZION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>PERIODONTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC FUNCTION ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANIMAL BITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>BLOOD URINE PRESENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>METRORRHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>RHEUMATOID VASCULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The anti-CCP data were difficult to interpret and compare for trends due to the 2 different methods of analysis used and the high variability in the data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

